Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Cash from Operations (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Cash from Operations readings, the most recent being 14288000.0 for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 5.03% to 14288000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 51500000.0, a 4.98% decrease, with the full-year FY2025 number at 51500000.0, down 4.98% from a year prior.
  • Cash from Operations hit 14288000.0 in Q4 2025 for Avalo Therapeutics, up from 16365000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 5726000.0 in Q3 2022 to a low of 19187000.0 in Q2 2021.
  • Median Cash from Operations over the past 5 years was 11998500.0 (2022), compared with a mean of 11443950.0.
  • Biggest five-year swings in Cash from Operations: surged 135.15% in 2022 and later tumbled 443.89% in 2024.
  • Avalo Therapeutics' Cash from Operations stood at 17099000.0 in 2021, then skyrocketed by 76.96% to 3940000.0 in 2022, then grew by 29.8% to 2766000.0 in 2023, then tumbled by 443.89% to 15044000.0 in 2024, then increased by 5.03% to 14288000.0 in 2025.
  • The last three reported values for Cash from Operations were 14288000.0 (Q4 2025), 16365000.0 (Q3 2025), and 11347000.0 (Q2 2025) per Business Quant data.